Related Experiment Video

Updated: Mar 24, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.5K

[Angiotensin-receptor- and neprilysin-inhibition: a new option against heart failure]

Claudia Bruhn

    Medizinische Monatsschrift Fur Pharmazeuten
    |March 16, 2016
    PubMed

    Insights

    Sacubitril/valsartan (Entresto) significantly reduces cardiovascular death and heart failure hospitalizations in patients with chronic heart failure. This novel medication offers an alternative to traditional therapies like ACE inhibitors.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Chronic heart failure (NYHA Class II-IV) with reduced ejection fraction poses significant risks of cardiovascular death and hospitalization.
    • Current treatments include ACE inhibitors and angiotensin-receptor blockers (ARBs), but novel therapeutic strategies are needed.

    Purpose of the Study:

    • To evaluate the efficacy of sacubitril/valsartan compared to enalapril in reducing cardiovascular death and heart failure hospitalizations.
    • To assess the safety profile of sacubitril/valsartan in patients with chronic heart failure.

    Main Methods:

    • A clinical study comparing sacubitril/valsartan with enalapril in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
    • Patients received sacubitril/valsartan in conjunction with other heart failure therapies, replacing ACE inhibitors or ARBs.

    Main Results:

    • Sacubitril/valsartan demonstrated superiority over enalapril in reducing the combined risk of cardiovascular death and heart failure hospitalization.
    • Identified potential side effects including hypotension, angioedema, impaired renal function, and elevated serum potassium levels.

    Conclusions:

    • Sacubitril/valsartan is an effective therapeutic option for managing chronic heart failure, offering improved outcomes compared to enalapril.
    • Contraindications include pregnancy, breastfeeding, severe hepatic impairment (Child-Pugh C), and concurrent use with aliskiren in diabetic patients.

    More Related Videos

    A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

    A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

    Published on: October 26, 2020

    5.7K
    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

    Published on: May 26, 2022

    4.4K

    Related Concept Videos

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    1.4K
    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

    Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
    2.8K
    Antihypertensive Drugs: Direct Renin Inhibitors01:25

    Antihypertensive Drugs: Direct Renin Inhibitors

    The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
    1.8K
    Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

    Antihypertensive Drugs: Angiotensin II Receptor Blockers

    In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
    3.0K
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    508
    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    1.3K